Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

Fig. 3

Proportions of patients achieving low disease activity and remission over 84 weeks, respectively based on a, b DAS28(CRP) (≤ 3.2 and < 2.6), c, d CDAI (≤ 10 and ≤ 2.8), and e, f SDAI (≤ 11 and ≤ 3.3) (full analysis set; NRI). CDAI, Clinical Disease Activity Index; DAS28(CRP), Disease Activity Score of 28 joints with C-reactive protein; NRI, nonresponder imputation; QD, once daily; SDAI, Simplified Disease Activity Index

Back to article page